Papers/PMID:26905985
Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study.
The New Zealand medical journal2015The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
magnesium(2+) — increases forced expiratory volume in one second (FEV1)
Evidence strength: very limited.Findingreplicated ×1“Greater improvements were seen in FEV1 at T0, T60 and T120 compared to TB in magnesium group (at T120, mean percentage change in FEV1 was 27.07% with magnesium versus 11.39% in the placebo group, 95%CI 3.7 to 27.7, p=0.01).”
Quoted verbatim from Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study.. - Study
- RCT
- Dose
- 2 g magnesium sulphate intravenously, single infusion
- Population
- Adults presenting to the emergency department with an acute exacerbation of COPD, all receiving standard bronchodilator therapy; magnesium sulphate given intravenously versus saline
Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study.2015PMID:26905985Permalink